Publication | Closed Access
Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment
55
Citations
18
References
2014
Year
The trough level 4.1μg/mL may serve as cut-off for clinical remission. Drug trough levels decreased during treatment and almost all patients with undetectable s-infliximab and monotherapy had developed antibodies against the drug.
| Year | Citations | |
|---|---|---|
Page 1
Page 1